Risk factors for hearing loss in neonates
Abstract
Background An estimated 6 of 1,000 children with live births suffer from permanent hearing loss at birth or the neonatal period. At least 90% of cases occur in developing countries. Hearing loss should be diagnosed as early as possible so that intervention can be done before the age of 6 months. Objective To determine risk factors for hearing loss in neonates. Methods We performed a case-control study involving 100 neonates with and without hearing loss who were born at Sanglah Hospital, Denpasar from November 2012 to February 2013. Subjects were consisted of 2 groups, those with hearing loss (case group of 50 subjects) and without hearing loss (control group of 50 subjects). The groups were matched for gender and birth weight. We assessed the following risk factors for hearing loss: severe neonatal asphyxia, hyperbilirubinemia, meningitis, history of aminoglycoside therapy, and mechanical ventilation by Chi-square analysis. The results were presented as odds ratio and its corresponding 95% confidence intervals. Results Seventy percent of neonates with hearing loss had history of aminoglycoside therapy. Multivariable analysis revealed that aminoglycoside therapy of 14 days or more was a significant risk factor for hearing loss (OR 2.7; 95%CI 1.1 to 6.8; P=0.040). There were no statistically significant associations between hearing loss and severe asphyxia, hyperbilirubinemia, meningitis, or mechanical ventilation. Conclusion Aminoglycoside therapy for >=14 days was identified as a risk factor for hearing loss in neonates.
References
Rukmini S. Uji bisik modifikasi sebagai sarana untuk skrining gangguan pendengaran di sekolah dasar. Media IDI. 2000;25:1-4.
Olusanya BO, Newton VE. Global burden of childhood hearing impairment and disease control priorities for developing countries. Lancet. 2007;369:1314-7.
Schulman-Galambos C, Galambos R. Brain stem evoked response audiometry in newborn hearing screening. Arch Otolaryngol. 1979;105:86-90.
Rundjan L, Amir I, Suwento R, Mangunatmadja I. Skrining gangguan pendengaran pada neonatus risiko tinggi. Sari Pediatri. 2005;6:149-54.
Stewart JE, Stolz JW. Hearing loss in neonatal intensive care unit graduates. New York: McGraw-Hill; 2008. p. 644-7.
Schleiss MR. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J. 2006;47:65-72.
Rivera LB, Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics. 2002;110:762-7.
Usami S, Abe S, Akita J, Shinkawa H, Kimberling WJ. Sensorineural hearing loss associated with the mitochondrial mutations. Adv Otorhinolaryngol. 2000;56:203-11.
Hille ET, van Straaten HI, Verkerk PH, Dutch NICU Neonatal Hearing Screening Working Group. Prevalence and independent risk factors for hearing loss in NICU infants. Acta Paediatr. 2007;96:1155-8.
Zamani A, Daneshjou K, Ameni A, Takand J. Estimating the incidence of neonatal hearing loss in high risk neonates. Acta Med Iran. 2004;42:176-80.
Korres S, Nikolopoulos TP, Komkotou V, Balatsouras D, Kandiloros D, Constantinou D, et al. Newborn hearing screening: effectiveness, importance of high risk factors, and characteristics of infants in the neonatal intensive care unit and well-baby nursery. Otol Neurotol. 2005;26:1186- 90.
Sastroasmoro S, Madiyono B, Moeslichan S, Budiman I, Purwanto SH. Estimates of the sample size. In: Sastroasmoro S, Ismael S, editors. Dasar-dasar metodologi penelitian klinis. 4th ed. Jakarta: CV Sagung Seto; 2011. p. 29-56.
Beaubien AR, Ormsby E, Bayne A, Carrier K, Crossfield G, Downes M, et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother. 1991;35:1070-4.
Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. Ototoxicity of amikasin. Antimicrob Agents Chemother. 1976;9:956-61.
Jurkovicova J, Aghova L, Abdel H, Elm W, Huttova M. Hearing impairment in premature infants in relation to risk factors for hearing loss. Intl Pediatr. 2002;17:172-8.
Lima GM, Marba ST, Santos MF. Hearing screening in a neonatal intensive care unit. J Pediatr (Rio J). 2006;82:110-4.
Meyer C, Witte J, Hildmann A, Hennecke KH, Schunck KU, Maul K, et al. Neonatal screening for hearing disorders in infants at risk: incidence, risk factors, and follow-up. Pediatrics. 1999;104:900-4.
Beaubien AR, Desjardins S, Ormsby E, Bayne A, Carrier K, Cauchy MJ, et al. Delay in hearing loss following drug administration. A consistent feature of amikacin ototoxicity. Acta Otolaryngol. 1990;109:345-52.
Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. Arch Dis Child Fetal Neonatal Ed. 2008;93:462-8.
Scott M. The prevalence of hyperbilirubinemia as a risk factor for hearing loss in newborn [thesis]. [St. Louis]: Washington University Department of Speech and Hearing; 2002.
Robertson CM, Howarth TM, Bork DL, Dinu IA. Permanent bilateral sensory and neural hearing loss of children after neonatal intensive care because of extreme prematurity: a thirty-year study. Pediatrics. 2009;123:797-807.
Brookhouser PE. Sensorineural hearing loss in children. Pediatr Clin North Am. 1996;43:1195-216.
Picciotti PM, Agostino SE, Di Nardo W, Scarano E. Scanning electron microscopy of cochlea in newborn rats exposed to hyperbaric oxygen: preliminary report. Acta Otorhinolaryngol Ital. 2005;25:267-70.
Northern JL, Downs MP. Medical aspects of hearing loss. Baltimore: Williams & Wilkins; 1991. p. 61-100.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Accepted 2016-02-12
Published 2016-11-30
